Crossroads: the role of biomarkers in the management of lumps in the breast
PDF | Full Text | How to cite | Press Release | Video Interview
Metrics: PDF 83 views | Full Text 461 views | ?
Georg F. Weber1
1 University of Cincinnati Academic Health Center, Cincinnati, OH 45267, USA
|Georg F. Weber,||email:||[email protected]|
Keywords: breast cancer premalignant lesion; biomarker; biopsy; mammography
Received: February 28, 2023 Accepted: March 28, 2023 Published: April 24, 2023
Premalignant lesions in the breast pose a difficult decision-making problem, whether to treat proactively and accept the side effects or to engage in watchful waiting and possibly encounter a later diagnosis of invasive cancer. A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system. The gene products of tumor progression may be expressed in early non-cancerous (“premalignant”) lesions, where they are associated with a high probability for full transformation in breast cancers. One such molecule is the OPN splice variant-c. OPN-c is also present in a fraction of the premalignant lesions, where it reflects an elevated risk for progression to cancer within 5 years, regardless of the lesion’s subtype. This marker has the properties needed to facilitate decisions to treat at the premalignant stage.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.